UNITED THERAPEUTICS CORP (UTHR) Stock Fundamental Analysis
USA - NASDAQ:UTHR - US91307C1027 - Common Stock
417.57 USD
+7.7 (+1.88%)
417.57 USD
0 (0%)
We assign a fundamental rating of 7 out of 10 to UTHR. UTHR was compared to 538 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making UTHR a very profitable company, without any liquidiy or solvency issues. UTHR is valued quite cheap, while showing a decent growth score. This is a good combination! This makes UTHR very considerable for value and quality investing!
1. Profitability
1.1 Basic Checks
UTHR had positive earnings in the past year.
In the past year UTHR had a positive cash flow from operations.
In the past 5 years UTHR has always been profitable.
Each year in the past 5 years UTHR had a positive operating cash flow.
1.2 Ratios
UTHR has a Return On Assets of 15.71%. This is amongst the best in the industry. UTHR outperforms 95.91% of its industry peers.
Looking at the Return On Equity, with a value of 17.31%, UTHR belongs to the top of the industry, outperforming 94.98% of the companies in the same industry.
UTHR's Return On Invested Capital of 16.17% is amongst the best of the industry. UTHR outperforms 96.47% of its industry peers.
UTHR had an Average Return On Invested Capital over the past 3 years of 14.96%. This is in line with the industry average of 15.95%.
The 3 year average ROIC (14.96%) for UTHR is below the current ROIC(16.17%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 15.71% | ||
| ROE | 17.31% | ||
| ROIC | 16.17% |
ROA(3y)14%
ROA(5y)12.47%
ROE(3y)16.72%
ROE(5y)15.47%
ROIC(3y)14.96%
ROIC(5y)13.31%
1.3 Margins
The Profit Margin of UTHR (40.36%) is better than 97.96% of its industry peers.
In the last couple of years the Profit Margin of UTHR has grown nicely.
UTHR's Operating Margin of 50.06% is amongst the best of the industry. UTHR outperforms 99.63% of its industry peers.
UTHR's Operating Margin has improved in the last couple of years.
UTHR has a Gross Margin of 88.98%. This is amongst the best in the industry. UTHR outperforms 90.33% of its industry peers.
UTHR's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 50.06% | ||
| PM (TTM) | 40.36% | ||
| GM | 88.98% |
OM growth 3Y7.2%
OM growth 5Y2.85%
PM growth 3Y13.74%
PM growth 5YN/A
GM growth 3Y-1.27%
GM growth 5Y-0.58%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), UTHR is creating some value.
UTHR has less shares outstanding than it did 1 year ago.
UTHR has more shares outstanding than it did 5 years ago.
UTHR has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 18.35 indicates that UTHR is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 18.35, UTHR belongs to the best of the industry, outperforming 91.45% of the companies in the same industry.
UTHR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 18.35 |
ROIC/WACC1.64
WACC9.87%
2.3 Liquidity
A Current Ratio of 7.26 indicates that UTHR has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 7.26, UTHR is in the better half of the industry, outperforming 70.26% of the companies in the same industry.
A Quick Ratio of 6.94 indicates that UTHR has no problem at all paying its short term obligations.
With a decent Quick ratio value of 6.94, UTHR is doing good in the industry, outperforming 68.96% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.26 | ||
| Quick Ratio | 6.94 |
3. Growth
3.1 Past
UTHR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 17.74%, which is quite good.
Measured over the past years, UTHR shows a quite strong growth in Earnings Per Share. The EPS has been growing by 16.88% on average per year.
The Revenue has grown by 17.62% in the past year. This is quite good.
Measured over the past years, UTHR shows a quite strong growth in Revenue. The Revenue has been growing by 14.71% on average per year.
EPS 1Y (TTM)17.74%
EPS 3Y34.86%
EPS 5Y16.88%
EPS Q2Q%9.57%
Revenue 1Y (TTM)17.62%
Revenue growth 3Y19.52%
Revenue growth 5Y14.71%
Sales Q2Q%11.71%
3.2 Future
Based on estimates for the next years, UTHR will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.46% on average per year.
Based on estimates for the next years, UTHR will show a small growth in Revenue. The Revenue will grow by 6.73% on average per year.
EPS Next Y12.62%
EPS Next 2Y7.94%
EPS Next 3Y5.16%
EPS Next 5Y11.46%
Revenue Next Year11.6%
Revenue Next 2Y8.44%
Revenue Next 3Y7.31%
Revenue Next 5Y6.73%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 16.30 indicates a correct valuation of UTHR.
95.35% of the companies in the same industry are more expensive than UTHR, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 27.38. UTHR is valued slightly cheaper when compared to this.
A Price/Forward Earnings ratio of 14.57 indicates a correct valuation of UTHR.
Compared to the rest of the industry, the Price/Forward Earnings ratio of UTHR indicates a rather cheap valuation: UTHR is cheaper than 94.80% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of UTHR to the average of the S&P500 Index (22.86), we can say UTHR is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.3 | ||
| Fwd PE | 14.57 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, UTHR is valued cheaper than 96.65% of the companies in the same industry.
UTHR's Price/Free Cash Flow ratio is rather cheap when compared to the industry. UTHR is cheaper than 95.54% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 17.63 | ||
| EV/EBITDA | 8.87 |
4.3 Compensation for Growth
UTHR's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
UTHR has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)1.29
PEG (5Y)0.97
EPS Next 2Y7.94%
EPS Next 3Y5.16%
5. Dividend
5.1 Amount
No dividends for UTHR!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
417.57
+7.7 (+1.88%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners100.6%
Inst Owner Change-1.82%
Ins Owners1.76%
Ins Owner Change4.02%
Market Cap18.89B
Analysts79.05
Price Target472.79 (13.22%)
Short Float %6.08%
Short Ratio3.74
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-4.95%
Min EPS beat(2)-9.46%
Max EPS beat(2)-0.45%
EPS beat(4)0
Avg EPS beat(4)-4.06%
Min EPS beat(4)-9.46%
Max EPS beat(4)-0.45%
EPS beat(8)3
Avg EPS beat(8)-1.6%
EPS beat(12)6
Avg EPS beat(12)-0.99%
EPS beat(16)7
Avg EPS beat(16)-3.25%
Revenue beat(2)1
Avg Revenue beat(2)2.03%
Min Revenue beat(2)-2.65%
Max Revenue beat(2)6.71%
Revenue beat(4)2
Avg Revenue beat(4)0.97%
Min Revenue beat(4)-2.65%
Max Revenue beat(4)6.71%
Revenue beat(8)6
Avg Revenue beat(8)2.26%
Revenue beat(12)8
Avg Revenue beat(12)1.8%
Revenue beat(16)10
Avg Revenue beat(16)1.71%
PT rev (1m)23.13%
PT rev (3m)20.47%
EPS NQ rev (1m)1.15%
EPS NQ rev (3m)-1.12%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.92%
Revenue NQ rev (1m)-0.67%
Revenue NQ rev (3m)-2.12%
Revenue NY rev (1m)-0.15%
Revenue NY rev (3m)-0.52%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.3 | ||
| Fwd PE | 14.57 | ||
| P/S | 6.14 | ||
| P/FCF | 17.63 | ||
| P/OCF | 13.77 | ||
| P/B | 2.63 | ||
| P/tB | 2.67 | ||
| EV/EBITDA | 8.87 |
EPS(TTM)25.62
EY6.14%
EPS(NY)28.66
Fwd EY6.86%
FCF(TTM)23.68
FCFY5.67%
OCF(TTM)30.32
OCFY7.26%
SpS68.05
BVpS158.6
TBVpS156.14
PEG (NY)1.29
PEG (5Y)0.97
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 15.71% | ||
| ROE | 17.31% | ||
| ROCE | 20.88% | ||
| ROIC | 16.17% | ||
| ROICexc | 27.55% | ||
| ROICexgc | 28.28% | ||
| OM | 50.06% | ||
| PM (TTM) | 40.36% | ||
| GM | 88.98% | ||
| FCFM | 34.8% |
ROA(3y)14%
ROA(5y)12.47%
ROE(3y)16.72%
ROE(5y)15.47%
ROIC(3y)14.96%
ROIC(5y)13.31%
ROICexc(3y)29.18%
ROICexc(5y)24.89%
ROICexgc(3y)30.03%
ROICexgc(5y)25.71%
ROCE(3y)19.31%
ROCE(5y)17.18%
ROICexcg growth 3Y23.22%
ROICexcg growth 5Y4.92%
ROICexc growth 3Y22.46%
ROICexc growth 5Y5.97%
OM growth 3Y7.2%
OM growth 5Y2.85%
PM growth 3Y13.74%
PM growth 5YN/A
GM growth 3Y-1.27%
GM growth 5Y-0.58%
F-Score6
Asset Turnover0.39
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 376.79% | ||
| Cap/Sales | 9.76% | ||
| Interest Coverage | 58.37 | ||
| Cash Conversion | 84.62% | ||
| Profit Quality | 86.22% | ||
| Current Ratio | 7.26 | ||
| Quick Ratio | 6.94 | ||
| Altman-Z | 18.35 |
F-Score6
WACC9.87%
ROIC/WACC1.64
Cap/Depr(3y)347.88%
Cap/Depr(5y)280.91%
Cap/Sales(3y)8.54%
Cap/Sales(5y)7.36%
Profit Quality(3y)85.86%
Profit Quality(5y)98.64%
High Growth Momentum
Growth
EPS 1Y (TTM)17.74%
EPS 3Y34.86%
EPS 5Y16.88%
EPS Q2Q%9.57%
EPS Next Y12.62%
EPS Next 2Y7.94%
EPS Next 3Y5.16%
EPS Next 5Y11.46%
Revenue 1Y (TTM)17.62%
Revenue growth 3Y19.52%
Revenue growth 5Y14.71%
Sales Q2Q%11.71%
Revenue Next Year11.6%
Revenue Next 2Y8.44%
Revenue Next 3Y7.31%
Revenue Next 5Y6.73%
EBIT growth 1Y21.63%
EBIT growth 3Y28.12%
EBIT growth 5Y17.97%
EBIT Next Year19.78%
EBIT Next 3Y5.56%
EBIT Next 5Y-4.6%
FCF growth 1Y59%
FCF growth 3Y31.3%
FCF growth 5YN/A
OCF growth 1Y58%
OCF growth 3Y30.42%
OCF growth 5YN/A